Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Aug 2026

Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

Abstract Background We evaluated baseline hypertension prevalence and control and risk of major adverse cardiovascular events (MACEs) among people with HIV in REPRIEVE who had low to moderate traditional cardiovascular disease (CVD) risk. Methods Hypertension at baseline was defined by (1) a preexisting diagnosis regar...

Risa M. Hoffman, Maya Watanabe, E. Martínez et al. · 0 citations
Open access Jul 2026

Inflammatory, Cardiac, and Lipid-Related Biomarkers in Relation to Residual MACE Risk in the REPRIEVE Trial

Background Residual major adverse cardiovascular event (MACE) risk persists despite successful prevention of cardiovascular disease (CVD) with statin therapy among people with HIV (PWH). Identifying key biomarkers related to residual cardiovascular risk is critical for PWH. Objectives The objective of the current analy...

S. Grinspoon, C. deFilippi, T. Umbleja et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.